Document is current

Article History

Received: 26 October 2024

Accepted: 2 April 2025

First Online: 15 April 2025

Declarations

:

: The study was conducted in accordance with the declaration of Helsinki and Good Clinical Practice guidelines. Documented approval from the competent independent ethic committee (EC) was obtained for all participating centers before start of the study, according to GCP, as well as local laws and regulations. When necessary, an extension, amendment or renewal of the EC approval was obtained. Informed consent was obtained from all trial subjects.

: S.F.: honoraria: BMS/Celgene. M.N.: honoraria: BMS/Celgene. J.H.: no conflicts of interest declared. A.H: no conflicts of interest declared. M.D.: honoraria: Astra Zeneca, Beigene, Gilead/Kite, Janssen, Lilly, Novartis, Roche; research support (institution): Abbvie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Lilly, Roche; scientific advisory board: Abbvie, Astra Zeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Lilly/Loxo, Novartis, Roche. M.K.: no conflicts of interest declared. H.S.: honoraria: AbbVie, Amgen, Astra Zeneca, BMS/Celgene, Genzyme, GSK, Janssen, Oncopeptides, Pfizer, Roche, Sanofi, Stemline, Takeda; travel expenses: Amgen, BMS/Celgene, Janssen, Sanofi. M.P.: no conflicts of interest declared. N.S.: travel expenses: Beigene, CASI; research support: Abbvie, AstraZeneca, Janssen, Roche; stocks: BMS/Celgene. B.G.: research support: BMS/Celgene; travel expenses: Roche, Gilead/Kite, Novartis; honoraria: Miltenyi, Roche, Gilead/Kite, Novartis.